180 Wealth Advisors LLC Acquires 6,535 Shares of Amgen Inc. $AMGN

180 Wealth Advisors LLC raised its holdings in Amgen Inc. (NASDAQ:AMGN) by 63.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,870 shares of the medical research company’s stock after acquiring an additional 6,535 shares during the period. 180 Wealth Advisors LLC’s holdings in Amgen were worth $5,522,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of AMGN. Laurel Wealth Advisors LLC lifted its stake in Amgen by 27,765.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 6,700,621 shares of the medical research company’s stock valued at $1,870,880,000 after purchasing an additional 6,676,575 shares during the last quarter. Norges Bank acquired a new position in shares of Amgen during the second quarter worth $1,663,726,000. Capital World Investors lifted its stake in shares of Amgen by 11.5% in the 3rd quarter. Capital World Investors now owns 18,795,474 shares of the medical research company’s stock valued at $5,303,578,000 after acquiring an additional 1,935,876 shares during the last quarter. National Bank of Canada FI boosted its holdings in shares of Amgen by 237.7% during the 3rd quarter. National Bank of Canada FI now owns 1,226,372 shares of the medical research company’s stock valued at $346,076,000 after acquiring an additional 863,216 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of Amgen by 5.6% during the 2nd quarter. Charles Schwab Investment Management Inc. now owns 12,893,677 shares of the medical research company’s stock valued at $3,600,043,000 after acquiring an additional 687,735 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on AMGN shares. Wells Fargo & Company upped their target price on Amgen from $375.00 to $390.00 and gave the stock an “equal weight” rating in a report on Thursday. Cantor Fitzgerald lifted their price target on Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Citigroup boosted their price target on Amgen from $315.00 to $345.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Guggenheim upped their price objective on Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Finally, Royal Bank Of Canada raised their price objective on shares of Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and an average target price of $354.60.

Amgen Stock Down 0.6%

Shares of NASDAQ AMGN opened at $347.80 on Monday. The company’s 50 day moving average price is $360.29 and its 200-day moving average price is $328.11. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52-week low of $261.43 and a 52-week high of $391.29. The company has a market capitalization of $187.49 billion, a P/E ratio of 24.44, a price-to-earnings-growth ratio of 3.45 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, topping analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same quarter last year, the firm earned $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts forecast that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be given a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. Amgen’s dividend payout ratio is presently 70.84%.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.